관련근거
-Conn's Current Therapy 2023 > HYPERLIPIDEMIA
-Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14e (2022) > Chapter 37: Drug Therapy for Dyslipidemias
-Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th edition 2022 > Chapter 27. Lipoprotein Disorders and Cardiovascular Disease
-Fuster and Hurst's The Heart, 15e. 2022 > Chapter 10: Hypercholesterolemia, Hyperlipoprotein(a), Hypertriglyceridemia, and Low HDL
-Current Diagnosis & Treatment: Cardiology, 6e > Chapter 1: Lipid Disorders
-이상지질혈증 진료지침 제5판(2022), 한국지질·동맥경화학회 진료지침위원회
-2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, European Heart Journal (2021) 00, 1-111
-2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology 37 (2021) 1129？1150
-2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke, Journal of the Formosan Medical Association 121 (2022) 1363e1370
-Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease, JAMA Cardiol. 2019;4(7):691-695.
-Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019. 0, 1？9
-O'Donoghue, et al. Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation. 2022;146:1109？1119
-Keech, Anthony C., et al. Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects―A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial―. Circulation Journal 85.11 (2021): 2063-2070.
-HAO, et al. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome. Int Heart J, July 2022; 63:669-677
-Marc S. Sabatine, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-22.
-Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018;379:2097-2107.
-Jennifer G. Robinson. et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 2015;372:1489-1499.
-Paul Muntner, et al. Evaluating a simple approach to identify adults meeting the 2018 AHA/ACC cholesterol guideline definition of very high risk for atherosclerotic cardiovascular disease. Cardiovascular Drugs and Therapy (2022) 36:475-481.
-CADTH, Recommendation (2017.11.) EVOLOCUMAB (REPATHA ― AMGEN CANADA INC)
-PBAC _ Public Summary Document ？ July 2022
-NICE : Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394) _ 22 June 2016
-INESSS(July 2020) Repatha™
-Cigna _ Drug and Biologic Coverage Policy_ IP0195 (Effective Date: 10/1/2022)
-AETNA _ July 01, 2020
-HAS_ 8 DECEMBER 2021, evolocumab, REPATHA 140 mg solution for injection in pre-filled pen, Re-evaluation